Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | GLA | P06280 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | CLK1 | P49759 | 1/20 | 0.45 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | MET | P08581 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | FASN | P49327 | 1/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.43 |
| ▸ | KDM5A | P29375 | 1/20 | 0.43 |
| ▸ | BTK | Q06187 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21051654 | 0.82 | ALDH1A1 (0.48) | ALDH1A1KDM4EGAACYP19A1CYP11B2 | |
| SCHEMBL10985180 | 0.81 | KDM4E (0.55) | ALDH1A1KDM4EGLAGAAL3MBTL1 | |
| SCHEMBL4474609 | 0.80 | MDM2 (0.62) | ALDH1A1KDM4EGLAGAAL3MBTL1 | |
| SCHEMBL3519224 | 0.78 | NPY5R (0.57) | CYP11B2HPGDNPY5RBTK | |
| SCHEMBL9701575 | 0.78 | MDM2 (0.59) | ALDH1A1KDM4EGLAGAAL3MBTL1 | |
| SCHEMBL11537629 | 0.77 | POLB (0.54) | ALDH1A1GAALMNACYP3A4CYP1A2 | |
| SCHEMBL11838343 | 0.76 | TYMP (0.51) | ALDH1A1CYP19A1CYP11B2HPGDNPY5R | |
| SCHEMBL10911458 | 0.74 | PDE3A (0.71) | ALDH1A1KDM4EGAALMNAHPGD | |
| SCHEMBL8402665 | 0.74 | KDM4E (0.70) | ALDH1A1KDM4EGLAGAACYP19A1 | |
| SCHEMBL9700724 | 0.74 | KDM4E (0.66) | ALDH1A1KDM4EGLAGAAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1646125-A | Substituted pyridones as modulators of P38MAP kinase | PHARMACIA CORP (US) | 2005-07-27 | — | — | CN | claimed |
| US-20040058964-A1 | Substituted pyridinones | PHARMACIA LLC | 2004-03-25 | — | — | US | claimed |
| CN-101531631-B | Substituted pyridinones as modulators of p38 map kinase | PHARMACIA CORP | 2011-09-28 | — | — | CN | disclosed |
| US-7629363-B2 | antiinflammatory agent for treating asthma and chronic pulmonary inflammatory disease | PFIZER INC (US) | 2009-12-08 | — | — | US | disclosed |
| CN-101531631-A | Substituted pyridinones as modulators of p38 map kinase | PHARMACIA CORP (US) | 2009-09-16 | — | — | CN | disclosed |
| CN-100486576-C | Substituted pyridones as modulators of P38MAP kinase | PHARMACIA CORP (US) | 2009-05-13 | — | — | CN | disclosed |
| US-7067540-B2 | Substituted pyridinones | PHARMACIA CORPORATION (US) | 2006-06-27 | — | — | US | disclosed |
| US-20050176775-A1 | Substituted pyridinones | PHARMACIA CORPORATION | 2005-08-11 | — | — | US | disclosed |
| CN-1646125-A | Substituted pyridones as modulators of P38MAP kinase | PHARMACIA CORP (US) | 2005-07-27 | — | — | CN | disclosed |
| WO-2005018557-A2 | SUBSTITUTED PYRIDINONES | PHARMACIA CORPORATION (US) | 2005-03-03 | — | — | WO | disclosed |
| US-20040058964-A1 | Substituted pyridinones | PHARMACIA LLC | 2004-03-25 | — | — | US | disclosed |
| US-3948903-A | Substituted N-(1,2-dihydro-2-oxonicotinyl)-cephalexins and -cephaloglycins | PARKE, DAVIS & COMPANY (US) | 1976-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058964-A1 | Substituted pyridinones | MAPK1, MAPK6, MAPK7 | ALDH1A1 787/4885KDM4E 3869/4885GLA 2495/4885 |
| US-20050176775-A1 | Substituted pyridinones | MAPK1, MAPK6, MAP3K6 | ALDH1A1 741/4885KDM4E 3921/4885GLA 2867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.